Allergan has recently obtained FDA approval for its groundbreaking skincare product, Skinvive, which is part of the Juvederm dermal filler collection. This innovative formula combines hyaluronic acid (HA) and a small amount of lidocaine injected into the facial skin for enhanced hydration and smoothing effects. Distinguished by its novel delivery mechanism, Skinvive effortlessly permeates the skin, leaving behind a radiant and long-lasting glow, as stated in a recent press release by Allergan.
Skinvive has been approved for use in adults aged 21 and above, encompassing all Fitzpatrick skin types ranging from light to dark (types I-VI). Its effects are noted to last for six months, and the procedure is minimally invasive, requiring little to no downtime, as affirmed by the company.
The FDA’s approval was substantiated by a pivotal clinical study involving Skinvive, which revealed that 58% of participants experienced skin improvement of more than one point on the Allergan Cheek Smoothness Scale after one month, with 56% still experiencing benefits after six months. The study also highlighted some mild to moderate side effects reported by participants, including temporary redness, swelling, itching, and discoloration. These reactions were generally well-tolerated and dissipated within 30 days.
